1. Home
  2. BOLD vs BGSF Comparison

BOLD vs BGSF Comparison

Compare BOLD & BGSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • BGSF
  • Stock Information
  • Founded
  • BOLD 2018
  • BGSF 2007
  • Country
  • BOLD United States
  • BGSF United States
  • Employees
  • BOLD N/A
  • BGSF N/A
  • Industry
  • BOLD
  • BGSF Professional Services
  • Sector
  • BOLD
  • BGSF Consumer Discretionary
  • Exchange
  • BOLD Nasdaq
  • BGSF Nasdaq
  • Market Cap
  • BOLD 33.4M
  • BGSF 37.4M
  • IPO Year
  • BOLD 2024
  • BGSF N/A
  • Fundamental
  • Price
  • BOLD $1.25
  • BGSF $3.26
  • Analyst Decision
  • BOLD Buy
  • BGSF Strong Buy
  • Analyst Count
  • BOLD 4
  • BGSF 1
  • Target Price
  • BOLD $4.00
  • BGSF $9.00
  • AVG Volume (30 Days)
  • BOLD 143.3K
  • BGSF 73.3K
  • Earning Date
  • BOLD 11-05-2025
  • BGSF 11-05-2025
  • Dividend Yield
  • BOLD N/A
  • BGSF 61.16%
  • EPS Growth
  • BOLD N/A
  • BGSF N/A
  • EPS
  • BOLD N/A
  • BGSF N/A
  • Revenue
  • BOLD N/A
  • BGSF $266,615,000.00
  • Revenue This Year
  • BOLD N/A
  • BGSF N/A
  • Revenue Next Year
  • BOLD N/A
  • BGSF $3.14
  • P/E Ratio
  • BOLD N/A
  • BGSF N/A
  • Revenue Growth
  • BOLD N/A
  • BGSF 28.60
  • 52 Week Low
  • BOLD $1.00
  • BGSF $2.91
  • 52 Week High
  • BOLD $3.75
  • BGSF $8.22
  • Technical
  • Relative Strength Index (RSI)
  • BOLD 40.98
  • BGSF 28.20
  • Support Level
  • BOLD $1.37
  • BGSF $3.28
  • Resistance Level
  • BOLD $1.52
  • BGSF $3.56
  • Average True Range (ATR)
  • BOLD 0.07
  • BGSF 0.13
  • MACD
  • BOLD -0.03
  • BGSF 0.08
  • Stochastic Oscillator
  • BOLD 6.25
  • BGSF 0.00

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About BGSF BGSF Inc.

BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.

Share on Social Networks: